Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany

Value in Health

Volumn 9, Issue 1, 2006, Pages 12-23

  Jansen, Jeroen P ^a   Kern, Winfried V ^b   Cornely, Oliver A ^c   Karthaus, Meinolf ^d   Ruhnke, Markus ^e   Ullmann, Andrew J ^f   Resch, Ansgar ^f  

^a MAPI GROUP   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d EVANGELISCHES KRANKENHAUS   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f PFIZER INC   (United States)

Author keywords

Cost effectiveness analysis; Diagnosis related groups; Invasive aspergillosis; Reimbursement

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CEFTAZIDIME; HYDROCORTISONE; ITRACONAZOLE; MEROPENEM; PARACETAMOL; PETHIDINE; PIPERACILLIN PLUS TAZOBACTAM; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CLINICAL PATHWAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; DRUG COST; DRUG SUBSTITUTION; ECONOMIC EVALUATION; GERMANY; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SOCIETY; SURVIVAL TIME;

EID: 33644931623     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00076.x     Document Type: Article

References (17)

1. Bohme A Ruhnke M Buchheidt D et al. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol 2003 82 Suppl. 2 S133 40
2. Ruhnke M Bohme A Buchheidt D et al. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Diagnosis of invasive fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol 2003 82 Suppl. 2 S141 8
3. Denning DW Invasive aspergillosis Clin Infect Dis 1998 26 781 803
4. Dixon DM McNeil MM Cohen ML et al. Fungal infections: a growing threat Public Health Rep 1996 111 226 35
5. Lamagni TL Evans BG Shigematsu M Johnson EM Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9) Epidemiol Infect 2001 126 397 414
6. Groll AH Shah PM Mentzel C et al. Trends in the postmortem epidemiology of invasive fungal infections at a University hospital J Infect 1996 33 23 32
7. Groll AH Ritter J Muller FM [Prevention of fungal infections in children and adolescents with cancer] Klin Padiatr 2001 213 Suppl. 1 S50 68
8. Lin SJ Schranz J Teutsch SM Aspergillosis case-fatality rate: systematic review of the literature Clin Infect Dis 2001 32 358 66
9. Dismukes WE Introduction to antifungal drugs Clin Infect Dis 2000 30 653 7
10. Herbrecht R Denning DW Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 2002 347 408 15
11. Wilson LS Reyes CM Stolpman M et al. The direct costs and incidence of systemic fungal infections Value Health 2002 5 26 34
12. Wenzel R Del Favero A Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients J Antimicrob Chemother 2005 55 352 61
13. Coleman MP Gatta G Verdecchia A et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century Ann Oncol 2003 14 Suppl. 5 S128 49
14. G-DRG-Fallpauschalen-Katalog 2005. Available from G-DRG via: [Accessed August 30, 2005].
15. Einheitlicher Bewertungsmaßstab (EBM). Available from online-EBM via: [Accessed August 30, 2005].
16. Gelbe Liste Pharmindex. Available from Medizinische Medien Informations GmbH via: [Accessed May 2004].
17. Lewis JS Boucher HW Lubowski TJ et al. Cost advantage of voriconazole over amphotericin B deoxycholate for the primary treatment of invasive aspergillosis Pharmacotherapy 2005 25 839 46